Innovent Biologics IPO Preview: Limited Upside on China's PD-1 Drug Market Compared to BeiGene
Innovent Biologics Inc (1641475D HK) is the fourth pre-profit biotech firm to IPO in Hong Kong since Ascletis Pharma Inc (1672 HK), BeiGene Ltd...
689 Views
Last Week in GER Research: Haidilao, Popflops, Bitmain, Shandong Gold, Niu and China Renaissance
Below is a recap of the key IPO research produced by the Global Equity Research team. This week we highlight 25% potential downside at Haidilao as...
388 Views
Last Week in GER Research: Meituan, IPO Trading Strategy, Shandong Gold, Maoyan and Viomi
Below is a recap of the key IPO research produced by the Global Equity Research team. This week we highlight that Meituan is closer to fair value...
330 Views
Last Week in GER Research: Meituan, Nio, Haidilao, Shandong Gold, China Renais., X Financial and PDD
Below is a recap of the key IPO research produced by the Global Equity Research team. This week we dig into the economics of Mobike as it relates...
361 Views
Last Week in GER Research: Meituan, China Tower, Haidilao, Qutoutiao, Hua Med., Chunlai, and Cootek
Below is a recap of the key IPO research produced by the Global Equity Research team. This week we assess Meituan's latest results ahead of its...
318 Views